Supporting Information

Noninvasive real-time monitoring of local drug release using nano Au-absorbed self-decomposable SiO$_2$ carriers

Li Fan$^{1,2,##}$, Jingnan Yang$^{2,##}$, Ken Cham-Fai Leung$^3$, Chaojun Song$^4$*, Quan Li$^2$*

Contents

Figure S11 Zeta potential of the AuNPs was determined by Delsa Nano C particle analyzer.

Figure S12. (a) Cumulative drug release profile up to 10 days (b) TEM images showing the morphological evolution of the Au-SiO$_2$ NPs dispersed in H$_2$O from 6 hrs. to 6 days.

Figure S13 TEM morphologies of Au-SiO$_2$ NPs before and after wash by centrifugation at 8000 rpm in DI water for 3 times. Almost all the free AuNPs were removed after wash. All scale bars were at 50 nm.

Figure S14 TEM morphological evolution of the Au-SiO$_2$ NPs was also observed in PBS. Samples were collected at 6, 12, 24, and 96 hrs, respectively. All scale bars were at 50 nm.

Figure S15 Drug release profile in PBS up to 12 days.
Figure SI6 Drug release profile in Colo-205 cells (a) cumulative, and (b) in every 6 hrs.

Figure SI7 The obtained tumor reconstructing images of pure AuNP treatment group from the CT data sets recorded as a function of time.

Figure SI8 The obtained tumor reconstructing images of MB loaded dense SiO$_2$ absorbing Au NPs treatment group from the CT data sets recorded as a function of time.

Figure SI9 Flow cytometry analysis showing the specific binding capability of Au-SiO$_2$-mAb NPs system to Colo-205 cells. The x-axis represented the fluorescence intensity of MB. FL4-H represented the emission collected using a channel of 650-750 nm, when being excited at 633 nm.

Figure SI10 The cumulative drug release profile of (a) Au-SiO$_2$ and (b) Au-SiO$_2$-mAb NPs during 48 hrs.

Figure SI11 (a) A typical set of data showing the voxel number ratio plotted as a function of the normalized CT values at different time points. The CT value of each voxel at specific time points was extracted from the 3D image data sets. Gaussian fitting was employed to find the most probable CT value (named as CT peak value afterwards). (b) The CT peak values plotted as a function of time, and the Sigmoidal fitting. The error bars were obtained by the same method as illustrated in Figure 4. (c) The cumulative drug (MB) release profile up to 48 hrs at the tumor site. At each time point, 3 mice were sacrificed and the respective MB release was measured. (d) The relationship between tumor CT values and drug release in tumor. All of the data of (c-
d) are reported as the means ± S.D. Sigmoidal fittings were performed by OriginPro9.1 software.

SI videos: The 3D videos of the tumor, as obtained by reconstructing images from the CT data sets recorded as a function of time.

0h-NP: 3D videos of the tumor just after administration of Au-SiO$_2$ NPs

3h-NP: 3D videos of the tumor at 3 hrs after administration of Au-SiO$_2$ NPs

6h-NP: 3D videos of the tumor at 6 hrs after administration of Au-SiO$_2$ NPs

9h-NP: 3D videos of the tumor at 9 hrs after administration of Au-SiO$_2$ NPs

12h-NP: 3D videos of the tumor at 12 hrs after administration of Au-SiO$_2$ NPs

15h-NP: 3D videos of the tumor at 15 hrs after administration of Au-SiO$_2$ NPs

18h-NP: 3D videos of the tumor at 18 hrs after administration of Au-SiO$_2$ NPs

21h-NP: 3D videos of the tumor at 21 hrs after administration of Au-SiO$_2$ NPs

24h-NP: 3D videos of the tumor at 24 hrs after administration of Au-SiO$_2$ NPs

3h-NP-mAb: 3D videos of the tumor at 3 hrs after administration of Au-SiO$_2$-mAb NPs

6h-NP-mAb: 3D videos of the tumor at 6 hrs after administration of Au-SiO$_2$-mAb NPs

9h-NP-mAb: 3D videos of the tumor at 9 hrs after administration of Au-SiO$_2$-mAb NPs

12h-NP-mAb: 3D videos of the tumor at 12 hrs after administration of Au-SiO$_2$-mAb NPs
18h-NP-mAb: 3D videos of the tumor at 18 hrs after administration of Au-SiO$_2$-mAb NPs

Free SiO$_2$ NP: 3D videos of the tumor at 24 hrs after administration of SiO$_2$ NPs

TEM tomography: TEM tomography videos for Au-SiO$_2$ NPs.

Figure S11 Zeta potential of the AuNPs was determined by Delsa Nano C particle analyzer.
**Figure S12.** (a) Cumulative drug release profile up to 10 days (b) TEM images showing the morphological evolution of the Au-SiO$_2$ NPs dispersed in H$_2$O from 6 hrs. to 6 days.
Figure SI3 TEM morphologies of Au-SiO\(_2\) NPs before and after wash by centrifugation at 8000 rpm in DI water for 3 times. Almost all the free AuNPs were removed after wash. All scale bars were at 50 nm.

Figure SI4 TEM morphological evolution of the Au-SiO\(_2\) NPs was also observed in PBS. Samples were collected at 6, 12, 24, and 96 hrs, respectively. All scale bars were at 50 nm.
Figure S15 Drug release profile in PBS up to 12 days.

Figure S16 Drug release profile in Colo-205 cells (a) cumulative, and (b) in every 6 hrs.

Figure S17 The obtained tumor reconstructing images of pure AuNP treatment group from the CT data sets recorded as a function of time.
Figure S18 The obtained tumor reconstructing images of MB loaded dense SiO$_2$ absorbing Au NPs treatment group from the CT data sets recorded as a function of time.

Figure S19 Flow cytometry analysis showing the specific binding capability of Au-SiO$_2$-mAb NPs system to Colo-205 cells. The x-axis represented the fluorescence intensity of MB. FL4-H represented the emission collected using a channel of 650-750 nm, when being excited at 633 nm.
Figure SI10 The cumulative drug release profile of (a) Au-SiO$_2$ and (b) Au-SiO$_2$-mAb NPs during 48 hrs
Figure SI11 (a) A typical set of data showing the voxel number ratio plotted as a function of the normalized CT values at different time points. The CT value of each voxel at specific time points was extracted from the 3D image data sets. Gaussian fitting was employed to find the most probable CT value (named as CT peak value afterwards). (b) The CT peak values plotted as a function of time, and the Sigmoidal fitting. The error bars were obtained by the same method as illustrated in Figure 4. (c) The cumulative drug (MB) release profile up to 48 hrs at the tumor site. At each time point, 3 mice were sacrificed and the respective MB release was measured. (d) The relationship between tumor CT values and drug release in tumor. All of the data of (c-d) are reported as the means ± S.D. Sigmoidal fittings were performed by OriginPro9.1 software.

The standard deviation of the fitting curves of normalized CT value-drug release rate in tumor site in two treatment groups, NP with and without mAb, were calculated by the function below.

\[
f(x)_{\text{standard deviation between the two plots}} = \int_{0.3}^{0.55} |y_1(x_1) - y_2(x_1)| \, dx
\]

\[
y_1(x_1) = a_1 + \frac{a_2 - a_1}{1 + 10^{(lg1 - col(x_1)) \cdot p}}
\]

\[
a_1=0.01637; a_2=0.89935; lg1=0.46115; p=10.37738;
\]

\[
y_2(x_1) = a_3 + \frac{a_4 - a_3}{1 + 10^{(lg1' - col(x_1)) \cdot p'}}
\]

\[
a_3=0.04768; a_4=0.78154; lg1'=0.43343; p'=13.21776;
\]